CPS score in head and neck cancer — what the number actually decides

No. Most people treated for head and neck cancer in India never need a CPS score. Standard treatment is surgery, radiation and chemotherapy, chosen by stage. Checkpoint inhibitor immunotherapy is considered mainly for cancer that has returned after treatment or has spread, and cannot be removed by surgery or safely irradiated again.

That matters more here than almost anywhere in India. Tobacco, gutka and areca-nut use give Telangana and Andhra Pradesh one of the country’s heaviest oral and throat cancer loads, and most are still found while surgery and radiation can treat them. For that large group no CPS test is needed at all. Being told you are not a candidate is not bad news here — it usually means the curative-intent pathway is still open.

CPS enters the picture in a narrower situation: recurrent or metastatic head and neck squamous cell cancer, where local treatment is exhausted and a systemic option is being chosen. Only then does it matter whether the tumour carries PD-L1.

At CION, immunotherapy is given as a day-care infusion — you come in, receive it, and go home the same day. The PD-L1 CPS test itself is coordinated through accredited partner pathology laboratories; it is specialist pathology work, not done in-house at a consultation. The wider picture is on our immunotherapy for head and neck cancer page.

CPS stands for Combined Positive Score. A pathologist counts every PD-L1-staining cell on the slide — tumour cells plus the immune cells among them — divides that by the total number of viable tumour cells, and multiplies by 100. It is reported as a plain number, not a percentage, and by convention it is capped at 100.

Two things in that formula surprise most patients. The immune cells count: lymphocytes and macrophages around the tumour are included, which is what “combined” refers to. And the result is a ratio, not a share — a CPS of 30 does not mean thirty per cent of the tumour is positive.

Because immune-cell staining is folded in, CPS is usually a higher number than a TPS would be on the very same tissue. That is a property of the formula, not a sign that your cancer is worse. Comparing your CPS against someone else’s TPS, or against a cut-off quoted for a different cancer, is the commonest way patients frighten themselves unnecessarily.

For the general terminology across all cancers, see our companion page on the PD-L1 score — TPS and CPS explained.

Thresholds shown are the commonly cited cut-offs from published companion-diagnostic labelling and NCCN head and neck guidance, indicative as of August 2026. Guidelines are revised periodically, and your oncologist confirms which cut-off applies to the specific plan being considered for you.

The tumour board reads the score next to several other facts, any one of which can change the plan more than CPS does:

• Where the cancer started — oral cavity, oropharynx, larynx and hypopharynx do not behave identically.
• HPV or p16 status — in oropharyngeal cancers especially, this changes how the disease is expected to behave.
• What you have already had — previous radiation dose and fields, previous chemotherapy, and how long ago.
• Whether local treatment is truly exhausted — salvage surgery or re-irradiation is sometimes still possible, and usually preferred when it is.
• Organ function and fitness — kidney and liver function, weight, swallowing, and how you are managing day to day.
• Whether a clinical trial fits — trials are informational here, never a promise of enrolment, but worth asking about.

One practical point gets missed: a sample can read PD-L1 negative when the tissue block was small, old or poorly preserved. If the result does not fit your clinical picture, it is reasonable to ask whether the tissue was adequate, and whether repeat testing would change anything.

1. 1

   The existing tissue block is traced

   Usually the paraffin block from your original biopsy or surgery. It often sits in a different hospital from the one treating you now, and retrieving it is frequently the slowest step.

2. 2

   Adequacy is checked

   There must be enough viable tumour tissue left to stain and score. If a small biopsy was used up on the original diagnosis, a repeat biopsy may be needed first.

3. 3

   Immunohistochemistry staining

   Thin sections are stained with a validated PD-L1 antibody assay at an accredited partner laboratory. The assay used is recorded on the report and matters when results are compared later.

4. 4

   The pathologist scores and reports

   Stained tumour and immune cells are counted against total viable tumour cells and the CPS is calculated. The report is then read against the cut-off relevant to the treatment being considered — at CION, in tumour board, not by one doctor alone.

Indicative as of August 2026, from published companion-diagnostic labelling and NCCN guidance. If your report carries the score your cancer does not normally use, ask which one the treatment under discussion is validated against.

• Eating and Nutrition on Immunotherapy for Head and Neck Cancer — eating strategies when swallowing, taste or a dry mouth is already a daily problem.
• Immunotherapy for Oesophageal Cancer — the neighbouring cancer that also uses CPS, with its own cut-off.
• Immunotherapy for Stomach and Gastro-Oesophageal Cancer — the same score read against a different threshold.
• Immunotherapy at CION Cancer Clinics — the whole pathway, from eligibility to day-care infusion and follow-up.

This page explains general PD-L1 CPS terminology for education only. It does not interpret any individual patient’s report, nor recommend any specific medicine. Cut-offs cited are indicative as of August 2026 and follow published companion-diagnostic labelling and NCCN head and neck guidance. PD-L1 CPS testing is coordinated at accredited partner pathology laboratories; immunotherapy at CION is given as a day-care infusion. Bring your report to a consultation for a doctor’s assessment.

Head and neck cancer is the cancer this region sees most

Tobacco, gutka and areca-nut use make oral and throat cancers unusually common across Telangana and Andhra Pradesh. Our oncologists explain every report in plain Telugu or English, with time to ask questions.